OncoMatch

OncoMatch/Clinical Trials/NCT04830267

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Is NCT04830267 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Camrelizumab for nasopharyngeal carcinoma.

Phase 2RecruitingChongqing University Cancer HospitalNCT04830267Data as of Jun 2026Location: China

Treatment: CamrelizumabCamrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Camrelizumab

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

WBC ≥ 2 K/microliter; Neutrophils ≥ 1.5 K/microliter; Platelets ≥ 100 K/microliter; Hemoglobin ≥ 9.0 g/deciliter

Kidney function

Serum Creatinine ≤ 1.5 x ULN or creatinine clearance > 40ml/min using the Cockcroft-Gault formula

Liver function

AST/ALT ≤ 3 x ULN; Total bilirubin <1.5 x ULN (except subjects with Gilbert Syndrome who can have total bilirubin <3.0 mg/deciliter)

Screening laboratory values must meet the following criteria (using CTCAE v4.0): WBC ≥ 2 K/microliter Neutrophils ≥ 1.5 K/microliter Platelets ≥ 100 K/microliter Hemoglobin ≥ 9.0 g/deciliter Serum Creatinine ≤ 1.5 x ULN or creatinine clearance > 40ml/min ... AST/ALT ≤ 3 x ULN Total bilirubin <1.5 x ULN (except subjects with Gilbert Syndrome who can have total bilirubin <3.0 mg/deciliter).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04830267 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify